Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients
FSHD1
Exercise and Myopathies. Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients: Functional, Tissue and Quality of Life Benefits.
3 other identifiers
interventional
15
1 country
2
Brief Summary
It is now accepted that physical activity is not deleterious in myopathies, including muscular dystrophies. In patients suffering from facioscapulohumeral dystrophy (FSHD), aerobic training has been reported to be associated to physiological and functional positive effects without alteration in quality of life. The review papers from Van der Kooi et al. (2005), Cup et al. (2007) and Féasson et al. (2010) suggest that the combination of endurance and strength training is even more relevant. Only a few controlled and randomized studies have been conducted on this topic. The impact of such training programs on the skeletal muscle regenerative capacities has not been yet addressed. Moreover, due to the fact that training programs are mainly performed on short-term supervised periods, there is a lack of knowledge regarding long-term effects, patient's autonomy and whether or not regular exercise practice can be maintained in patient's daily life. Also, only a few experiments have reported an integrative view of the potential benefits of such programs on functional, biological and quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2010
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2010
CompletedFirst Posted
Study publicly available on registry
May 5, 2010
CompletedStudy Start
First participant enrolled
October 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2015
CompletedApril 1, 2015
March 1, 2015
4.3 years
April 28, 2010
March 31, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
maximal oxygen uptake (VO2max)
VO2max is meseasured directly by respiratory gas analysis during maximal exercise test on ergocycle
Week 24
Secondary Outcomes (5)
Questionnaire of quality of life
Day 0, Week 6, Week 12, Week 18 and Week 24
Biopsy
Day 0 and Week 24
maximal oxygen uptake (VO2max)
Week 6, Week 12 and Week 18
Questionnaire of subjective fatigue
Day 0, Week 6, Week 12, Week 18 and Week 24
nuclear magnetic resonance imaging
Inclusion
Study Arms (2)
Physical training
EXPERIMENTALThe training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
control
OTHERNone intervention
Interventions
Eligibility Criteria
You may qualify if:
- facioscapulohumeral dystrophy
- Being capable of supporting an exercise on ergocycle
- Social Security regimen affiliated
- Consent form signed
You may not qualify if:
- Severe cardiac or respiratory insufficiency
- Cardiac pacemaker
- Morbid obesity (BMI upper to 35)
- Anti platelet therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHU de Grenoble
Grenoble, 38000, France
CHU de Saint-Etienne
Saint-Etienne, 42055, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Leonard FEASSON, MD-PhD
CHU de Saint-Etienne
- STUDY CHAIR
Fawzi KADI, MD-PhD
Orebro University, Sweden
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2010
First Posted
May 5, 2010
Study Start
October 1, 2010
Primary Completion
January 1, 2015
Study Completion
January 1, 2015
Last Updated
April 1, 2015
Record last verified: 2015-03